Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Hepatotoxicity and related risk factors of severe hepatotoxicity among HIV-1 infected individuals initiated on highly active antiretroviral therapy (HAART) in Cameroon
13th Euro-Global Gastroenterology Conference
Lem Edith Abongwa, Anthony Kebira Nyamache, Fokunang Charles, Judith Torimiro, Nshom Emmanuel, Irenee Domkam and Paul Okemo
University of Bamenda, CameroonKenyatta University, KenyaChantal Biya International Reference Center for Research on HIV/AIDS prevention and management, CameroonUniversity of Yaoundé I, CameroonMbingo Baptist Hospital – CBCHS, Cameroon
Aims/Purpose: Hepatotoxicity due to highly active antiretroviral therapy (HAART) has gained prominent attention since it can be
affected by many factors. The aim of this study was to determine the prevalence of hepatotoxicity and related risk factors of severe
hepatotoxicity following HAART initiation.
Methods: One hundred naive HIV-1 patients were recruited and followed up for 24 weeks. They were placed on either
Tenofovir (TDF)+Lamivudine (3TC)+Efavirenz(EFV) or Zidovudine (AZT)+Lamivudine+Nevirapine (NVP) or
Zidovudine+Lamivudine+Efavirenz regimen. Venous blood samples were collected to measure trans aminotransferases (ALT and
AST) and alkaline phosphatase (ALP), using colometric enzymatic reaction which were used to classified hepatotoxicity based on age
and sex.
Results: A total of 38 (38%) and 55 (55%) patients presented with hepatotoxicity while 15% and 28% of patients of them had severe
hepatotoxicity at 4 and 24 weeks respectively. Serum levels of all enzymes increased significantly (p<0.05) with increased treatment
duration. Univariate analysis revealed that the risk factor of developing severe hepatotoxicity was significantly (p<0.05) greater in
patients <30years, males, low BMI, low monthly income earners and patient on AZT+3TC+ NVP regimen. While multivariate analysis
showed that age <30 years, Low BMI, low monthly income and the use of AZT+3TC+NVP was an independent risk factors.
Conclusions: Low BMI, <30years, low monthly income and the use of AZT+3TC+NVP regimen were identifiable risk factors for the
development of severe hepatotoxicity. As such these factors should be considered as an important strategy by clinicians in preventing
the hepatotoxicity.
Recent Publications:
1. Lem E A et al. (2018) Incidence of elevated aminotransferases levels among patients presenting with hepatitis syndrome in the
northwest region of Cameroon. Cohesive J. Microbiol. Infect. Dis. 1(1):1-5.
2. Lem E A et al. (2017) Knowledge, practice and prevalence of Helicobacter pylori infection in the north west region of
Cameroon. Clinical Biotechnology and Microbiology. 1(4):135-143.
3. Lem E A et al. (2017) Hepatotoxicity and anaemia co-morbidity in treated HIV patients in Fundong subdivision in the
northwest region of Cameroon. Microbiology Research Journal International. 18(5):1-10.
4. Lem E A, Nyuydzedze S S and Ndifor G A (2016) Assessment of knowledge, attitude and practice towards hepatitis B among
two rural communities of the anglophone regions in Cameroon. IRA-International Journal of Applied Sciences. 4(3):490-505.
5. Lem E A and Penn K (2016) Assessing prevalence and risk factors of hepatitis B surface antigen amongst pregnant women
attending antenatal clinic in the northwest region of Cameroon. European Journal of Research in Medical Sciences. 4(1):32-
43.
Biography
Lem Edith Abongwa, a Medical Microbiologist is pursuing PhD from Kenyatta University, Kenya. She is also an Assistant Lecturer at the University of Bamenda, Cameroon. Her research interest is on HIV and Hepatitis B virus. She is interested in the identification and assessment of risk factors that expose communities to these infections and possible solutions to prevent and control them as well as parasite strain diversity and severity to infectious infection. Prior to medical research she was the Head of a public health non-governmental organization assessing the implementation of option B+ in two regions of Cameroon sponsored by a PEPFAR HIV/AIDS project in Cameroon.